CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet statistical significance thresholds for its primary endpoint of change in the Clinical Dementia Rating Sum of Boxes, CDR-SB, or any of its key secondary endpoints – change from baseline in Timed Up and Go, TUG, test, change from baseline in a Neuropsychological Test Battery, NTD, and the Clinician’s Global Impression of Change, CGIC. Initial analysis shows that target plasma drug concentrations were not achieved during the double-blind phase of the trial, which may have adversely impacted trial results.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CRVO:

• CervoMed initiated with Buy into ‘binary readout’ at Roth MKM

• CervoMed initiated with a Buy at Roth MKM

• CervoMed initiated with a Buy at H.C. Wainwright

• CervoMed Enhances Transparency with Key Information Access

• CervoMed announces ODD granted to neflamapimod by U.S. FDA